Cargando…

Effects of ABCB1 DNA methylation in donors on tacrolimus blood concentrations in recipients following liver transplantation

AIMS: To investigate the effects of ABCB1 DNA methylation in donors on individual differences in tacrolimus blood concentrations following liver transplantation. METHODS: Twenty‐three donor liver samples carrying the CYP3A5*3/*3 genotype were classified into 2 groups based on their initial tacrolimu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Chengcheng, Yan, Liang, Gao, Jie, Chen, Shitong, Zhang, Lirong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542360/ https://www.ncbi.nlm.nih.gov/pubmed/35487881 http://dx.doi.org/10.1111/bcp.15376

Ejemplares similares

Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2021)

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation
por: Chen, Yi-kuan, et al.
Publicado: (2014)

Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients
por: Yan, Lin, et al.
Publicado: (2019)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

SARS-CoV-2 and Tacrolimus Blood Concentration in Kidney Transplant Recipients
por: McMinn, Jason, et al.
Publicado: (2021)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients—The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy
por: Bodnar-Broniarczyk, Magdalena, et al.
Publicado: (2021)

Evaluation of clotrimazole prophylaxis on tacrolimus trough concentrations in kidney transplant recipients
por: Wings, Emily, et al.
Publicado: (2022)

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
por: Sapisochin, Gonzalo, et al.
Publicado: (2022)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
por: Wu, Zhengshan, et al.
Publicado: (2013)

Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function
por: Han, Seung Seok, et al.
Publicado: (2016)

Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients
por: Zhu, Huaijun, et al.
Publicado: (2022)

Blood Profiles of Gut Bacterial Tacrolimus Metabolite in Kidney Transplant Recipients
por: Guo, Yukuang, et al.
Publicado: (2020)

A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes
por: Riegersperger, Markus, et al.
Publicado: (2019)

Genomewide association study identifies a novel variant associated with tacrolimus trough concentration in Chinese renal transplant recipients
por: Yang, Siyao, et al.
Publicado: (2022)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient
por: Zhou, Shuang-Nan, et al.
Publicado: (2020)

Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19
por: Pearson, Meredith M., et al.
Publicado: (2021)

A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients
por: Koomen, Jeroen V., et al.
Publicado: (2023)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients
por: Undre, Nasrullah, et al.
Publicado: (2021)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient
por: Chan, Samuel, et al.
Publicado: (2017)

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
por: Bremer, Sebastian C. B., et al.
Publicado: (2018)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients
por: Franken, Linda G., et al.
Publicado: (2022)

Using Tacrolimus in Living Donor Liver Transplantation Recipients with High Model for End-stage Liver Disease Scores Might Increase the Risk of Postoperative Neuropsychologic Deficits
Publicado: (2013)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

Recipient Outcomes with Younger Donors Undergoing Living Donor Liver Transplantation
por: Dar, Faisal S, et al.
Publicado: (2019)

The International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline
por: Miller, Charles M., et al.
Publicado: (2017)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
por: Kim, Hyeyoung, et al.
Publicado: (2014)

Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2022)

Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients
por: Ko, Hyunmin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnfdgb0blkikpo697bt5davuqp